Latest News
In accordance with Article 13 of Law No. 104-12 on freedom of prices and competition and Article 10 of Decree No. 2-14-652 adopted for its implementation, as amended and supplemented, the Competition Council makes available to the public the “operation summary” below, containing the information provided by the parties.
This information was prepared by the notifying parties, who are solely responsible. Any inaccurate or distorted information contained therein does not in any way prejudge the Competition Council’s position on the proposed operation.
The publication of this press release does not attest to the completeness of the file provided for in Article 9 of Decree No. 2-14-652 adopted for the implementation of Law No. 104-12 on freedom of prices and competition as amended and supplemented.
Names of the companies and groups involved:
- The indirect acquirer: the company “Sun Pharmaceutical Industries Limited”;
- The direct acquirer: the company “Sun Pharma America, Inc.”;
- The target: the company “Organon & Co.”.
Nature of the operation
- Exclusive control acquisition.
Economic sectors concerned
- Market for the supply of lipid regulators products (C10A);
- Market for the supply of Bone Calcium Regulators (M5B).
Deadline for interested third parties to submit their observations
- 10 days from the date of publication of this press release, i.e. July 13, 2026.
NON-CONFIDENTIAL SUMMARY OF THE OPERATION
PROVIDED BY THE PARTIES
The Competition Council received notification of an economic concentration operation concerning the indirect exclusive control acquisition by the company “Sun Pharmaceutical Industries Limited”, through the company “Sun Pharma America Inc.”, of the company “Organon & Co.”, by acquiring 100% of its share capital and related voting rights.
Sun Pharmaceutical Industries Limited is a limited liability company under Indian law, headquartered at SPARC, Tandalja, Vadodara – 390 012, Gujarat, India. It specializes in generics, is listed on the National Stock Exchange of India and BSE Limited (NSE: SUNPHARMA, BSE: 524715). Its portfolio covers cardiology, psychiatry, neurology, gastroenterology, and dermatology, including generics, branded generics, specialized and complex products, over-the-counter drugs, antiretrovirals, and Active Pharmaceutical Ingredients (APIs). Sun Pharma also has a segment dedicated to innovative drugs.
Sun Pharma America, Inc. is a Delaware corporation, a wholly-owned subsidiary of Sun Pharmaceutical Industries Limited or its affiliates, established solely for the purpose of this operation.
Organon & Co. is a Delaware corporation, headquartered at 1209 Orange St., Wilmington, New Castle County, DE 19801, United States. A spin-off from Merck & Co., Inc., Organon & Co. is currently listed on the New York Stock Exchange (NYSE: OGN). It operates in the health sector with a focus on women’s health. Its portfolio includes over 70 products, centered around three main areas: women’s health (including contraception and fertility), biosimilars, and established brands (mainly off-patent originals).
Done in Rabat, on July 2, 2026
